These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 25757)

  • 41. Comparison of medroxalol and labetalol, drugs with combined alpha- and beta-adrenoceptor antagonist properties.
    Elliott HL; McLean K; Meredith PA; Sumner DJ; Reid JL
    Br J Clin Pharmacol; 1984 May; 17(5):565-72. PubMed ID: 6145440
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antihypertensive actions of an isomer of labetalol and other vasodilator-beta-adrenoceptor blockers.
    Baum T; Sybertz EJ
    Fed Proc; 1983 Feb; 42(2):176-81. PubMed ID: 6130003
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combined alpha- and beta-adrenoreceptors blockade with oral labetalol in hypertensive patients with reference to haemodynamic effects at rest and during exercise.
    Koch G
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):729-32. PubMed ID: 10951
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acute haemodynamic effects of labetalol and its subsequent use of an oral hypotensive agent.
    Joekes AM; Thompson FD
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):789-93. PubMed ID: 990156
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Haemodynamic effects of long-term oral labetalol.
    Edwards RC; Raftery EB
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):733-6. PubMed ID: 791328
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hemodynamic effects of intravenous labetalol in essential hypertension.
    Dunn FG; Oigman W; Messerli FH; Dreslinski GR; Reisin E; Frohlich ED
    Clin Pharmacol Ther; 1983 Feb; 33(2):139-43. PubMed ID: 6822026
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical pharmacology of labetalol.
    Richards DA; Prichard BN
    Br J Clin Pharmacol; 1979; 8(Suppl 2):89S-93S. PubMed ID: 43165
    [No Abstract]   [Full Text] [Related]  

  • 48. Alpha and beta adrenoceptor blocking properties of labetalol and its R,R-isomer, SCH 19927.
    Sybertz EJ; Sabin CS; Pula KK; Vliet GV; Glennon J; Gold EH; Baum T
    J Pharmacol Exp Ther; 1981 Aug; 218(2):435-43. PubMed ID: 6114171
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of labetalol in moderate to severe hypertension.
    Macdonald I; Hua AS; Thomas GW; Woo KT; Whitworth JA; Kincaid-Smith P
    Med J Aust; 1980 Apr; 1(7):325-7. PubMed ID: 7393061
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacologic and physiologic considerations of adrenoceptor blockade.
    Frohlich ED; Dunn FG; Messerli FH
    Am J Med; 1983 Oct; 75(4A):9-14. PubMed ID: 6139019
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiovascular dynamics after acute and long-term alpha- and beta-adrenoceptor blockade at rest, supine and standing, and during exercise.
    Koch G
    Br J Clin Pharmacol; 1979; 8(Suppl 2):101S-105S. PubMed ID: 43162
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immediate effects of labetalol on central, splanchnic-hepatic, and forearm haemodynamics during pleasant emotional stress in hypertensive patients.
    Trap-Jensen J; Clausen JP; Hartling OJ; Svendsen TL; Krogsgaard AR
    Postgrad Med J; 1980; 56 Suppl 2():37-42. PubMed ID: 7433341
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Labetalol and pindolol in the treatment of hypertension: a comparative study.
    Romo M; Halttunen P; Saarinen P; Sarna S
    Ann Clin Res; 1979 Dec; 11(6):249-52. PubMed ID: 398184
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of labetalol, hydrallazine, and propranolol in the therapy of moderate hypertension.
    West MJ; Wing LM; Mulligan J; Walkley J; Grygiel JJ; Graham JR; Chalmers JP
    Med J Aust; 1980 Mar; 1(5):224-5. PubMed ID: 6990215
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sympathetic nervous activity and the pressor effect of noradrenaline under chronic alpha-beta-adrenoceptor blockade with labetalol in hypertension.
    Zschiedrich H; Neurohr W; Lüth JB; Philipp T; Distler A
    Klin Wochenschr; 1983 Jul; 61(13):661-7. PubMed ID: 6310204
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Labetalol and other agents that block both alpha- and beta-adrenergic receptors.
    Pearce CJ; Wallin JD
    Cleve Clin J Med; 1994; 61(1):59-69; quiz 80-2. PubMed ID: 8124849
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.
    Goa KL; Benfield P; Sorkin EM
    Drugs; 1989 May; 37(5):583-627. PubMed ID: 2663413
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Labetalol therapy in patients with systemic hypertension and angina pectoris: effects of combined alpha and beta adrenoceptor blockade.
    Frishman WH; Strom JA; Kirschner M; Poland M; Klein N; Halprin S; LeJemtel TH; Kram M; Sonnenblick EH
    Am J Cardiol; 1981 Nov; 48(5):917-28. PubMed ID: 6118060
    [No Abstract]   [Full Text] [Related]  

  • 59. Comparative trial of labetalol and acebutolol, alone or associated with dihydralazine, in treatment of essential hypertension.
    Thibonnier M; Lardoux MD; Corvol P
    Br J Clin Pharmacol; 1980 Jun; 9(6):561-7. PubMed ID: 6992823
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Malignant pheochromocytoma: blood pressure controlled by labetalol].
    Sugano O; Hirano J; Hirano K; Kubota Y; Numasawa K; Kawamura S
    Nihon Hinyokika Gakkai Zasshi; 1984 Mar; 75(3):523-7. PubMed ID: 6471663
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.